Jardiance Tablet, Film Coated
Product Images NDC 50090-6452

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Jardiance (NDC 50090-6452). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Jardiance 01)

Chemical structure of Empagliflozin, the active ingredient in Jardiance 10 mg film-coated tablets by A-S Medication Solutions. The structure shows the molecular arrangement including hydroxyl groups, a chlorine atom, and a dioxolane ring.*

FDA Label Image

Figure 1 (Jardiance 02)

A forest plot displaying the geometric mean ratios with 90% confidence intervals for AUC and Cmax values comparing various antidiabetic drugs and other medications when co-administered relative to empagliflozin alone. The y-axis lists drugs with their dosages, while the x-axis shows the change relative to empagliflozin alone, ranging from 50 to 200.*

FDA Label Image

Figure 2 (Jardiance 03)

A forest plot showing the geometric mean ratio with 90% confidence intervals for AUC and Cmax of various drugs. The drugs are categorized as antidiabetic drugs, oral contraceptives, and others, each with specified doses and single or daily administrations. The x-axis measures the geometric mean ratio ranging approximately from 50 to 150.*

FDA Label Image

Figure 3 (Jardiance 04)

A line graph showing mean percentage change from baseline in HbA1c over 24 weeks for three groups: placebo (N=185), empagliflozin 10 mg (N=206), and empagliflozin 25 mg (N=202). The graph indicates a decrease in HbA1c with empagliflozin doses compared to placebo, with error bars representing variability at week 24. The x-axis is labeled by weeks (Baseline, 6, 12, 18, 24) and the y-axis shows HbA1c mean change (%) from baseline.*

FDA Label Image

Figure 4 (Jardiance 05)

A line graph comparing the mean percentage change from baseline in HbA1c levels over 52 weeks between two treatment groups: Glimepiride plus Metformin (N=700) and Empagliflozin 25 mg plus Metformin (N=693). The X-axis represents time in weeks, and the Y-axis shows the percentage change in HbA1c. The graph includes a legend and error bars at week 52.*

FDA Label Image

Figure 5 (Jardiance 06)

A line graph comparing the percentage of patients with events over 48 months between placebo and Empagliflozin groups. The x-axis represents months, and the y-axis represents the percentage of patients with events. The graph includes a table showing the number of subjects at risk for each group at various time points.*

FDA Label Image

Figure 6 (Jardiance 07)

A line chart comparing the percentage of patients with events over 48 months between Placebo and Empagliflozin groups. The x-axis represents months, and the y-axis shows the percentage of patients with events. The chart includes a risk table below showing the number of subjects at risk at various time points for both groups.*

FDA Label Image

Qr Code (Jardiance 08)

FDA Label Image

Figure 7 (Jardiance 08a)

A cumulative incidence curve comparing estimated kidney function events over time between placebo and Empagliflozin 10 mg in patients. The graph shows percentage incidence on the y-axis and days since randomization on the x-axis, illustrating lower incidence rates for Empagliflozin versus placebo over about 810 days.*

FDA Label Image

Figure 8 (Jardiance 08b)

A Kaplan-Meier curve comparing the mean number of events over days since randomization for Empagliflozin 10 mg and placebo groups. The graph shows cumulative event rates with values plotted over approximately 810 days, indicating lower event rates for Empagliflozin 10 mg compared to placebo. Patient risk counts at various time points are provided below the graph.*

FDA Label Image

Figure 9 (Jardiance 08c)

A forest plot chart depicting hazard ratios with 95% confidence intervals comparing Empagliflozin 10 mg versus placebo across various subgroups, including diabetes status, age, sex, race, BMI, baseline eGFR, NYHA class, heart failure physiology, and baseline medication use. The horizontal axis represents hazard ratio values on a logarithmic scale, with markers indicating the direction and strength of effect favoring either Empagliflozin or placebo.*

FDA Label Image

Figure 10 (Jardiance 08d)

A Kaplan-Meier survival curve chart comparing estimated cumulative incidence percentages over days since randomization between placebo and Empagliflozin 10 mg groups. The x-axis shows days since randomization up to approximately 1170 days, and the y-axis shows estimated cumulative incidence in percent. The chart includes a table of patients at risk over time for both groups and a statistical summary of hazard ratio (HR 0.79, 95% CI 0.69-0.90) and p-value (0.0003) comparing Empagliflozin 10 mg versus placebo.*

FDA Label Image

Figure 11 (Jardiance 08e)

A line graph comparing the mean number of events over days since randomization for Empagliflozin 10 mg versus placebo. The y-axis represents the mean number of events, and the x-axis shows days up to 1170. Two lines indicate event curves for placebo and Empagliflozin 10 mg, with the Empagliflozin group showing fewer events consistently. The graph includes patient counts at risk for both groups below the x-axis and an inset text with hazard ratio, confidence interval, and p-value.*

FDA Label Image

Figure 12 (Jardiance 08f)

A forest plot chart showing hazard ratios comparing Empagliflozin 10 mg to placebo across various subgroups including diabetes status, age, sex, race, BMI, eGFR at baseline, NYHA class, LVEF at baseline, NT-proBNP levels, and baseline use of MRA. The chart presents hazard ratios with 95% confidence intervals and the number of events versus analyzed subjects for each subgroup, visually depicting the relative risk with squares and horizontal lines over a log-scale axis.*

FDA Label Image

Label Image (Lbl500906452)

Label for JARDIANCE (Empagliflozin) 10 mg film-coated tablets, oral use, manufactured by A-S Medication Solutions. The label indicates a package containing 90 tablets, with storage instructions to keep between 68 to 77 degrees Fahrenheit. The label includes product identification numbers and a QR code for dosage information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.